Financial Health Snapshot
What does Becton, Dickinson and Company’s latest financial snapshot show?
Mixed. Revenue strength is the best sign, but the main concern is leverage, especially after the latest quarter was distorted by restructuring charges and a loss from discontinued operations.
The latest verified period is FY2025, with added context from Q1 2026 and Q2 2026. This verdict combines growth, profitability, cash generation, balance-sheet capacity, and capital efficiency, so the rating reflects both operating momentum and the pressure from debt and one-time charges. For mission context, see Mission Statement, Vision, & Core Values (2026) of Becton, Dickinson and Company (BDX).
Investors should read the snapshot as a story of resilient demand, better per-share earnings conversion, and improving operating cash flow growth of 213%, offset by Q2 2026 net income of -$31100M and free cash flow growth of -055%; net debt deserves deeper analysis first.
Mixed Earnings Quality
Does Becton, Dickinson and Company revenue growth support quality earnings?
Mixed. Becton, Dickinson and Company showed strong reported revenue growth in FY2025, but the clearest divergence is that growth was helped by acquired and portfolio effects, while the latest quarter’s earnings were clouded by restructuring and discontinued operations.
Growth quantity and growth quality are not the same. In FY2025, Becton, Dickinson and Company reported Revenue: $218B, 82% reported growth, and 29% organic growth, so investors have to separate core demand from deal-driven and portfolio effects. That is why revenue durability is compared with operating income, net income, and EPS across compatible annual periods. For context on strategy and priorities, see Mission Statement, Vision, & Core Values (2026) of Becton, Dickinson and Company (BDX).
| Measure | Latest Period | Previous Period | Quality Test | Investor Meaning |
|---|---|---|---|---|
| Revenue | $218B, 82% reported growth, FY2025; 29% organic growth | Not provided | Mixed; reported growth was boosted by acquired and portfolio effects | Core growth looks weaker than reported growth, so repeatability is limited |
| Operating Income | $9400M, 2026-03-31 | Not provided | Unclear; latest-quarter growth was heavily distorted | Operating leverage is not a clean confirmation of revenue quality here |
| Net Income | -$31100M, with -$3700M from continuing operations and -$27400M from discontinued operations, 2026-03-31 | Not provided | Divestiture and restructuring effects dominated results | Final earnings do not confirm the reported revenue trend |
| Diluted EPS | -$111, 2026-03-31 | Not provided | Negative EPS reflects the weak reported earnings mix | Shareholders did not receive clean per-share confirmation |
How durable is Becton, Dickinson and Company revenue?
The strongest durability signal is 29% organic growth in FY2025, but the largest visibility limit is China, where revenue share is projected to decline to 40% of total sales in 2026 from 70% previously amid volume-based procurement headwinds.
- Demand Quality: FY2025 organic growth suggests real demand, but reported growth also reflects portfolio changes and acquisitions.
- Pricing and Volume: The price-volume split is not provided; China volume-based procurement pressure adds uncertainty to demand visibility.
- Diversification: The Advanced Patient Monitoring unit moved into BD Medical, and Biosciences and Diagnostic Solutions was spun off and merged with Waters Corporation.
That mix matters because durable revenue has to translate into cleaner profit and cash conversion.
Profitability and Cash Quality
Are Becton, Dickinson and Company profitability and cash flow improving?
Mixed to weak near term. Reported profit quality looks pressured by $5330M of restructuring charges, manufacturing network consolidation, and discontinued operations, while operating cash flow growth of 213% suggests better cash generation even as free cash flow growth of -055% leaves the overall picture uneven.
Becton, Dickinson and Company’s latest results separate cash and profit pretty clearly. Gross profit and operating income still exist, but net income turned negative because other expenses, taxes, and special charges outweighed the operating base. For the mission and strategy backdrop, see Mission Statement, Vision, & Core Values (2026) of Becton, Dickinson and Company (BDX).
| Measure | Latest Period | Previous Period | Verified Driver | Investor Meaning |
|---|---|---|---|---|
| Gross Margin | 45.7% for 2026-03-31, based on $215B gross profit and $256B cost of revenue | Unavailable | Cost of revenue was still heavy, while manufacturing network consolidation and mix effects weighed on reported economics | Product economics are not weak, but they are not yet showing clean margin expansion |
| Operating Margin | 2.0% for 2026-03-31, based on $9400M operating income | Unavailable | Operating expenses of $206B and $5330M restructuring charges limited operating leverage | Scale is not translating into strong operating efficiency right now |
| Net Margin | -6.6% for 2026-03-31, based on -$31100M net income | Unavailable | Other expenses of $59900M, income tax expense of $7600M, and discontinued operations reduced final profit quality | Final profitability does not confirm the operating result |
| Operating Cash Flow | 213% growth for 2026-03-31 | Unavailable | Receivables Growth: -1208% and Inventory Growth: -1782% point to working-capital release | Earnings are converting better into operating cash, but the absolute cash amount is not supplied |
| Free Cash Flow | Unavailable | Unavailable | Capex is not supplied, so the free cash flow burden cannot be verified | Remaining reinvestment and financing capacity cannot be measured from the supplied data |
What most affects Becton, Dickinson and Company cash conversion?
Working capital is the strongest visible driver, especially the -1208% receivables change and -1782% inventory change, which likely helped cash flow. That looks more temporary than structural, but the supplied data cannot confirm capex or absolute free cash flow.
- Main Driver: Working-capital release from receivables and inventory appears temporary, not a lasting margin fix.
- Evidence Gap: Absolute operating cash flow, capex, and free cash flow amounts are not supplied.
- Metric to Monitor: Gross margin and restructuring expense should show whether cash gains become durable.
Balance Sheet Strength
Is Becton, Dickinson and Company’s balance sheet strong enough after the Waters transaction?
Becton, Dickinson and Company’s balance sheet is Mixed. The main protection is $81600M in cash and short-term investments, while the main concern is still very high debt and goodwill and intangible assets after the Waters transaction.
Cash matters, but it is not enough on its own. For Becton, Dickinson and Company, the key test is whether working capital, asset quality, debt service, solvency, liquidity, and refinancing can all support the business at the same time. The Waters deal helped de-risk leverage, but the balance sheet still needs close monitoring.
| Area | Latest Evidence | Assessment | Investor Meaning |
|---|---|---|---|
| Cash and Working Capital | Cash And Cash Equivalents: $81300M; Cash And Short Term Investments: $81600M; Total Current Assets: $801B; Total Current Liabilities: $851B | Mixed | Near-term obligations look manageable, but current liabilities are larger than current assets, so liquidity still deserves attention. |
| Total and Net Debt | Short Term Debt: $257B; Long Term Debt: $1471B; Total Debt: $1728B; Net Debt: $1647B; Total Debt was $1954B at 2025-12-31 | Mixed | Leverage remains heavy, but the lower debt level shows deleveraging direction after the transaction. |
| Debt Service and Refinancing | Waters Corporation transaction valued at $40B; proceeds were used for debt reduction; management targets a Net Leverage Ratio of 2.5x by the end of calendar 2026 | Mixed | The financing plan supports pressure reduction, but debt still has to be paid down and refinanced with discipline. |
| Asset Quality | Goodwill And Intangible Assets: $3430B; Total Assets: $5083B | Mixed | Large intangible assets can weaken flexibility if they lose value, so impairment risk matters. |
| Liabilities and Equity | Total Liabilities: $2670B; Total Stockholders Equity: $2413B | Mixed | The equity base is solid, but liabilities are still large enough to limit financial flexibility. |
Which balance-sheet risk matters most for Becton, Dickinson and Company?
Debt reduction is the key issue. The biggest risk is still leverage, even though the Waters transaction and lower Total Debt from $1954B to $1728B point in the right direction.
- Current Exposure: Total Current Assets of $801B versus Total Current Liabilities of $851B.
- Protection: Cash And Short Term Investments of $81600M and proceeds from the $40B Waters transaction.
- Warning Signal: Watch whether debt keeps falling and whether Goodwill And Intangible Assets of $3430B stay stable.
Capital Efficiency
Can Becton, Dickinson and Company fund reinvestment and shareholder returns?
Capital efficiency is Mixed. Becton, Dickinson and Company appears able to support dividends and buybacks, but internal cash alone does not look fully enough to cover reinvestment, debt reduction, and large capital returns at the same time.
Return measures need to be read alongside leverage, asset intensity, capital spending, working capital, and any outside funding. For Becton, Dickinson and Company, the key issue is not just whether returns exist, but whether they are strong enough to fund reinvestment, reduce debt, and still support shareholder payouts without stretching the balance sheet.
| Capital Measure | Latest Evidence | Quality Test | Investor Meaning |
|---|---|---|---|
| ROIC | Unavailable in the supplied data for this block. | ROIC still needs to be judged against operating margin and asset discipline, not just size of earnings. | Shows whether invested capital is creating operating value rather than tying up cash in low-return assets. |
| ROE and ROA | Unavailable in the supplied data for this block. | ROE can be lifted by leverage, while ROA depends more on asset efficiency and balance-sheet intensity. | Helps investors separate true operating strength from debt-fueled shareholder return quality. |
| Maintenance and Growth Investment | Research And Development Expenses: $24900M for 2026-03-31; Rdexpense Growth: -2170%; $1100M investment to expand US pharmaceutical supply chain capacity for biologic drugs. | R&D and supply-chain expansion show active reinvestment, but the mix suggests both operating support and growth spending. | Indicates the capital needed to sustain innovation, capacity, and future operating scale. |
| Internal Funding Capacity | Net Debt: $1647B; Q2 2026 accelerated share repurchase of $20B supported by Waters Corporation transaction proceeds; January 27, 2026 authorization of a new 10M share repurchase program; Quarterly Dividend: $105 per common share; indicated annual rate of $420 per share at March 31, 2026. | Returns are being funded through a mix of operating cash, transaction proceeds, and balance-sheet management rather than pure internal free cash flow alone. | Suggests capital returns are supported, but leverage and reinvestment demands still limit flexibility and raise the importance of deleveraging. |
Are Becton, Dickinson and Company’s returns on capital sustainable?
Sustainability looks tied to portfolio simplification and cash generation, but leverage reduction is the key test because Net Debt: $1647B remains material and can pressure future returns if reinvestment or buybacks outrun cash flow.
- Operating Source: Portfolio simplification, dividend discipline, and supply-chain investment support returns while Becton, Dickinson and Company also keeps repurchases active.
- Funding Requirement: The largest verified needs are deleveraging, the $1100M biologic-drug supply-chain expansion, and ongoing shareholder payouts.
- Durability Test: Returns weaken if leverage stays high, free cash flow falls short of reinvestment, or the company must rely more on external funding; Mission Statement, Vision, & Core Values (2026) of Becton, Dickinson and Company (BDX) helps frame the strategy behind that capital mix.
Financial resilience risk
How resilient is Becton, Dickinson and Company (BDX), and which warning signs matter most?
Mixed. The main buffer is $40B in divestiture proceeds used for debt reduction, plus an investment-grade balance sheet. The most important verified warning sign is the $5,330M restructuring burden in Q2 2026, which signals heavy execution risk and near-term cash strain.
Becton, Dickinson and Company is still able to fund core operations, but resilience looks uneven because the company is carrying a large restructuring program while also dealing with regulatory and regional demand pressure. If margins weaken, cash generation slows, or refinancing needs rise, debt service and investment flexibility could tighten quickly.
| Pressure | Financial Effect | Existing Protection | Warning Signal |
|---|---|---|---|
| Revenue or Margin Pressure | Q2 2026 restructuring charges of $5,330M reduce earnings, depress operating leverage, and can weaken cash flow and debt capacity if the charges keep rising. | Management is consolidating the manufacturing network, and the company still has a GOOD financial health score and investment-grade credit ratings. | Another rise in restructuring charges, weaker margin trend, or lower operating cash flow would confirm deterioration. |
| Working-Capital or Investment Pressure | Restructuring, product testing, and plant disruption can absorb cash that would otherwise support capex, R&D, or inventory planning. | The company has divestiture proceeds available and can still use internal funding if operating cash flow stays stable. | Slower operating cash flow growth or a jump in cash tied up in operations would be the main sign to watch. |
| Interest or Refinancing Pressure | Debt reduction helps, but high restructuring spending can still reduce free cash flow and limit flexibility if rates or maturities become less favorable. | $40B in divestiture proceeds is being used for debt reduction, with a Net Leverage Ratio target of 2.5x by the end of calendar 2026. | Rising net debt, weaker interest coverage, or missed leverage progress would show pressure building. |
Which financial warning signs should investors monitor at Becton, Dickinson and Company?
First, watch restructuring charges and operating cash flow because they show confirmed strain. Second, monitor net debt and leverage progress. Third, the FDA Warning Letter and US ship hold are a future risk if they expand or last longer.
Q2 2026 restructuring burden
The $5,330M restructuring charges tied to manufacturing network consolidation are the clearest evidence of pressure. The company has a debt-reduction plan, but the next metric is whether restructuring charges keep falling and cash flow stays intact.
FDA Warning Letter and ship hold
The FDA Warning Letter for the El Paso, Texas site and the voluntary US ship hold on certain products create regulatory and operating disruption risk. The mitigating factor is management action; the next metric is product release timing and any expansion of the hold.
China revenue mix is shrinking
China revenue is projected to decline to 40% of total sales in 2026 from 70% previously, showing volume-based procurement headwinds. That matters because geographic pressure can weigh on growth and margins; monitor China revenue trend and mix.
Financial Health Scorecard
What does Becton, Dickinson and Company’s financial health mean for investors?
Overall, Becton, Dickinson and Company scores Mixed. The strongest factor is the balance sheet reset after debt reduction; the weakest is near-term profitability. The most important condition for the investment case is whether operating cash flow stays strong enough to support restructuring, investment, and deleveraging.
| Financial Factor | Rating | Evidence and Investor Meaning |
|---|---|---|
| Revenue and Earnings Quality | Mixed | FY2025 growth was positive, but Q2 2026 earnings turned negative, so the revenue base looks usable while per-share momentum is uneven. |
| Profitability and Cash | Weak | Net Income: -$31100M and Free Cash Flow Growth: -055% show pressure, even with Operating Cash Flow Growth: 213% supporting liquidity. |
| Balance Sheet and Liquidity | Strong | Total Debt fell to $1728B and Net Debt was $1647B, but Cash And Cash Equivalents was $81300M and current liabilities exceeded current assets. |
| Capital Efficiency | Mixed | BDX is funding R&D, manufacturing investment, dividends, repurchases, and debt reduction at the same time, which supports growth but keeps capital demands high. |
| Financial Resilience | Mixed | Deleveraging and hedging help, but restructuring, China headwinds, and the FDA Warning Letter add execution risk and can delay recovery. |
- What Supports the Thesis: Balance sheet reset, strong operating cash flow growth, and active deleveraging give Becton, Dickinson and Company room to absorb near-term strain.
- What Challenges the Thesis: Weak profitability, restructuring charges of $5330M, and regulatory and China-related pressure keep earnings quality uncertain.
- What to Monitor: Net Debt: $1647B, Operating Cash Flow Growth: 213%, restructuring charges of $5330M.
If you’re using this for a paper or case study, a structured SWOT Analysis, PESTLE Analysis, or Business Model Canvas can help organize the evidence, and the broader company context is available in Becton, Dickinson and Company (BDX): History, Ownership, Mission, How It Works & Makes Money. This scorecard should be used with forecasts and scenarios because the cash flow path will drive assumptions, risk cases, and valuation inputs.
FAQ
What Do Investors Ask About 's Financial Health?
Investors most often ask about the company's revenue quality, profitability, cash generation, debt, liquidity, capital efficiency, and ability to withstand financial pressure.
Why did BDX post a Q2 2026 net loss?
BDX reported Net Income: -$31100M for 2026-03-31 Company context attributes the Q2 2026 loss to $5330M in restructuring charges and a $2740M loss from discontinued operations, which clouded underlying earnings quality
How much debt reduction came from Waters deal?
The Waters Corporation transaction was valued at $40B, and company context says divestiture proceeds were used for debt reduction The supplied data does not state the exact amount of debt reduction already completed from the deal
What supports BDX dividend after divestitures?
Dividend support comes from operating cash generation, portfolio simplification, and deleveraging capacity At March 31, 2026, BDX reported Quarterly Dividend: $105 per common share, representing an indicated annual rate of $420 per share
Is BDX improving cash conversion after restructuring?
Cash conversion is mixed For 2026-03-31, Operating Cash Flow Growth was 213%, while Free Cash Flow Growth was -055% The data supports monitoring, not a firm conclusion, because absolute cash flow and capex values are not supplied
What liquidity risks should BDX investors monitor?
Investors should monitor Cash And Cash Equivalents: $81300M, Total Current Assets: $801B, Total Current Liabilities: $851B, Short Term Debt: $257B, and progress toward the Net Leverage Ratio target of 25x by the end of calendar 2026